

DRUG PRIOR AUTHORIZATION COMMITTEE

~~December 16, 2010~~

January 7, 2011

TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry, Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:30	Pharmacy Program/ Budget Update	George Oestreich/ Andrew Haslag
11:30 - 11:35	DUR Update	Rhonda Driver
	<u>Old Business</u>	
11:35 - 12:05	a. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
	b. Selzentry Clinical Edit	
	c. Ranexa Clinical Edit	
	d. Botox Clinical Edit	
	e. Human Papilloma Virus (HPV) Clinical Edit	
	<u>New Business</u>	
12:05 – 12:20	a. New Drug/Product Reviews Proposed Actions (See website and Attached Summary)	Rhonda Driver
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Products	
	iv. Prior Authorization	
	b. Clinical Edits	
	i. Stadol NS/butorphanol Clinical Edit	
	ii. Provigil/Nuvigil Clinical Edit	
	iii. Ampyra Clinical Edit	
12:20-1:00	c. Preferred Drug List (PDL)	
	I. Antihyperuricemics	
	• Discussion	
	• Public Hearing	
	• Decision	
	ii. Bile Salts	
	• Discussion	
	• Public Hearing	
	• Decision	
	ii Inhaled Antibiotics	
	• Discussion	
	• Public Hearing	
	• Decision	
	iii. Pancreatic Enzymes	
	• Discussion	
	• Public Hearing	
	• Decision	
	iv. Topical Analgesics	
	• Discussion	
	• Public Hearing	
	• Decision	
	c. <u>Preferred Drug List</u>	
	i. Process discussion	

ii. Therapeutic classes-to be *announced at meeting*

1:00	LUNCH	
1:00-1:15	<u>Program Utilization Information</u>	Rhonda Driver
1:15-1:30	<u>Other Business</u>	
	i. <i>Top 25" Drugs by Cost</i>	
	ii. <i>Clinical Edit Summary Report</i>	
	iii. <i>Call Center Statistics</i>	

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate - Agenda may move more quickly*

	<u>Executive Session</u>	
1:30-1:35	Minutes Review	Discussion/Approval
1:35-adjourn	Case Reviews	Jenna Twehus

NEXT MEETING: March 17, 2011 – 205 Jefferson Street, 10th Floor.